About Sandy Maniscalco

This author has not yet filled in any details.
So far Sandy Maniscalco has created 6 blog entries.

Arko Dasgupta, PhD

Arko Dasgupta, PhD Fred Hutchinson Cancer Research Center Breast cancer is a major killer in the United States and metastases are the primary cause of breast cancer-related deaths. Approximately 30% of breast cancer patients will develop metastases during their lifetime. Few prognostic factors predict metastases as well as the presence of dormant disseminated tumor [...]

Arko Dasgupta, PhD 2018-01-23T10:57:36+00:00

Sheng Sun, PhD

Sheng Sun, PhD Massachusetts General Hospital Cancer Center The majority of breast cancers express hormone receptors, and therapies that antagonize hormonal signaling via these receptors are the most effective treatments for hormone receptor-positive metastatic breast cancer (HR+ MBC). Unfortunately, for the vast majority of patients with hormonal therapy-refractory MBC, the mechanisms of resistance remain [...]

Sheng Sun, PhD 2018-01-23T10:57:04+00:00

Adrienne Gropper Waks, MD

Adrienne Gropper Waks, MD Dana-Farber Cancer Institute Following many important advances in treating HER2-positive breast cancer over the past two decades, a large majority of patients with non-metastatic HER2-positive tumors are cured with today’s treatments. For this majority of patients who do well in the long-term, we must begin to identify ways to cure HER2-positive [...]

Adrienne Gropper Waks, MD 2018-01-23T10:56:31+00:00

Ji Li, PhD

Ji Li, PhD Dana-Farber Cancer Institute Basal-like breast tumors comprise a heterogeneous group that accounts for about 15% of all breast cancers. They are highly aggressive and generally fail to respond to targeted therapies. Thus, there is a great need to identify novel vulnerabilities and develop novel therapies for this aggressive breast tumor type. The [...]

Ji Li, PhD 2017-07-05T10:48:04+00:00

Aaron Meyer, PhD

Aaron Meyer, PhD Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology Metastatic spread drives the majority of breast cancer mortality and, to do so, requires tumor cells to both disseminate and avoid clearance by the immune system. Inhibiting TAM receptors has shown promising results in models of breast cancer by [...]

Aaron Meyer, PhD 2018-01-21T07:39:49+00:00

Heather Parsons, MD

Heather Parsons, MD, MPH Dana-Farber Cancer Institute This year, breast cancer will claim the lives of more than 500,000 people worldwide. Most of these will be women in whom the disease has spread to the rest of the body, known as metastatic breast cancer. Women living with metastatic breast cancer typically receive ongoing, single-agent treatments [...]

Heather Parsons, MD 2017-07-05T10:51:17+00:00